美国 · SEC FORM 4
TScan Therapeutics, Inc.
TCRX · Nasdaq · CIK 0001783328 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
2 同一窗口内观察到的 Form 4 交易行
0 sales · 2 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
—
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2025-12-23 · Lynx1 Capital Management LP; Nichols Weston.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 2,486,277
- 上期报告
- 2,280,163
- 日均成交量
- 764,430
- 回补天数
- 3.2
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2025-12-23 | Lynx1 Capital Management LP; Nichols Weston | 买入 (P) | Common Stock | 6,232 | USD 0.90 | USD 5,609 | SEC 申报 ↗ |
| 2025-12-22 | Lynx1 Capital Management LP; Nichols Weston | 买入 (P) | Common Stock | 75,500 | USD 0.90 | USD 67,950 | SEC 申报 ↗ |
| 2025-12-19 | Lynx1 Capital Management LP; Nichols Weston | 买入 (P) | Common stock, $0.0001 par value per share ("Common Stock") | 80,069 | USD 0.90 | USD 72,062 | SEC 申报 ↗ |
| 2025-05-20 | Lynx1 Capital Management LP; Nichols Weston | 买入 (P) | Common Stock | 1,200,000 | USD 1.20 | USD 1,440,000 | SEC 申报 ↗ |
| 2025-05-19 | Lynx1 Capital Management LP; Nichols Weston | 买入 (P) | Common stock, $0.0001 par value per share ("Common Stock") | 1,388,794 | USD 1.20 | USD 1,666,553 | SEC 申报 ↗ |
| 2024-12-13 | Lynx1 Capital Management LP; Nichols Weston | 买入 (P) | Common Stock | 100,000 | USD 2.90 | USD 290,000 | SEC 申报 ↗ |
| 2024-12-12 | Lynx1 Capital Management LP; Nichols Weston | 买入 (P) | Common stock, $0.0001 par value per share ("Common Stock") | 31,800 | USD 3.01 | USD 95,718 | SEC 申报 ↗ |
| 2024-11-15 | Lynx1 Capital Management LP; Nichols Weston | 买入 (P) | Common stock, $0.0001 par value per share | 947 | USD 4.34 | USD 4,110 | SEC 申报 ↗ |
| 2024-09-23 | Klencke Barbara | 买入 (P) | Voting Common Stock | 5,000 | USD 5.29 | USD 26,450 | SEC 申报 ↗ |
| 2024-08-26 | Klencke Barbara | 买入 (P) | Voting Common Stock | 5,000 | USD 5.53 | USD 27,650 | SEC 申报 ↗ |
| 2024-08-23 | Klencke Barbara | 买入 (P) | Voting Common Stock | 5,000 | USD 5.69 | USD 28,450 | SEC 申报 ↗ |
| 2023-12-19 | BARBERICH TIMOTHY J | 买入 (P) | Voting Common Stock | 317 | USD 4.97 | USD 1,575 | SEC 申报 ↗ |
| 2023-12-18 | BARBERICH TIMOTHY J | 买入 (P) | Voting Common Stock | 28,830 | USD 4.89 | USD 140,979 | SEC 申报 ↗ |
| 2023-12-14 | Klencke Barbara | 买入 (P) | Voting Common Stock | 5,000 | USD 5.08 | USD 25,400 | SEC 申报 ↗ |
| 2023-06-02 | BARBERICH TIMOTHY J | 买入 (P) | Voting Common Stock | 37,880 | USD 2.63 | USD 99,624 | SEC 申报 ↗ |
Form 4 申报证据
5 transaction lines in the latest 365-day window; 52 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | ZDRAVESKI ZORAN | 奖励／授予 (A) | Voting Common Stock | 300,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-10-01 | MacBeath Gavin | 奖励／授予 (A) | Voting Common Stock | 1,000,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-23 | Lynx1 Capital Management LP; Nichols Weston | 买入 (P) | Common Stock | 6,232 | USD 0.90 | USD 5,609 | SEC 申报 ↗ |
展开近期 Form 4 证据 (5 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | ZDRAVESKI ZORAN | 奖励／授予 (A) | Voting Common Stock | 300,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-10-01 | MacBeath Gavin | 奖励／授予 (A) | Voting Common Stock | 1,000,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-23 | Lynx1 Capital Management LP; Nichols Weston | 买入 (P) | Common Stock | 6,232 | USD 0.90 | USD 5,609 | SEC 申报 ↗ |
| 2025-12-22 | Lynx1 Capital Management LP; Nichols Weston | 买入 (P) | Common Stock | 75,500 | USD 0.90 | USD 67,950 | SEC 申报 ↗ |
| 2025-12-19 | Lynx1 Capital Management LP; Nichols Weston | 买入 (P) | Common stock, $0.0001 par value per share ("Common Stock") | 80,069 | USD 0.90 | USD 72,062 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | TCRX |
| CIK | 0001783328 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2836 Biological Products, (No Diagnostic Substances) |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 52 transaction lines from 2021-07-20 to 2026-10-01 39 P purchase lines · 4 S sale lines · 9 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.